List of Excipients in Branded Drug CLARAVIS

Generic Drugs Containing CLARAVIS

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	isotretinoin	0555-1054	ALPHA-TOCOPHEROL
Teva Pharmaceuticals USA Inc	isotretinoin	0555-1054	BUTYLATED HYDROXYANISOLE
Teva Pharmaceuticals USA Inc	isotretinoin	0555-1054	D&C RED NO. 7

What are the Most Frequently-Used Excipients in CLARAVIS?

# Of NDCs	Excipient
1	.ALPHA.-TOCOPHEROL
1	ALPHA-TOCOPHEROL
1	AMMONIA

Claravis Excipient Strategy and Commercial Opportunities for Isotretinoin

Last updated: September 2, 2026

Claravis is an oral isotretinoin capsule for severe recalcitrant nodular acne. Its commercial position is driven by generic competition, teratogenicity controls, food-dependent absorption, and the cost and complexity of the iPLEDGE risk-management system. The strongest excipient opportunities are not basic capsule substitution. They are food-independent absorption, allergen and animal-origin reduction, improved stability, easier administration, and differentiated packaging or delivery formats.

What is Claravis and which excipients define its formulation?

Claravis contains isotretinoin, a highly lipophilic retinoid. The product is supplied as soft gelatin capsules in 10 mg, 20 mg, 30 mg, and 40 mg strengths. The labeled formulation uses an oil-based fill and a gelatin capsule shell. Listed inactive ingredients include soybean oil, hydrogenated vegetable oil, beeswax, gelatin, sorbitol, titanium dioxide, and strength-specific colorants, although the exact inactive-ingredient profile should be verified against the applicable FDA label and product listing.[1]

Attribute	Claravis
Active ingredient	Isotretinoin
Dosage form	Oral soft gelatin capsule
Strengths	10 mg, 20 mg, 30 mg, 40 mg
Primary indication	Severe recalcitrant nodular acne
Patient population	Adults and adolescents age 12 years and older, subject to labeling
Absorption issue	Food increases isotretinoin exposure
Risk-management system	iPLEDGE REMS
Formulation category	Lipid-filled softgel
Biologic status	Not applicable
Generic pathway	ANDA-based competition is available
Principal commercial constraints	Teratogenicity, REMS, food effect, generic pricing

Claravis labeling instructs patients to take the capsules with meals. The food requirement creates the main formulation weakness. A product that produces reliable exposure without a high-fat meal could obtain a meaningful clinical and commercial position, particularly for adolescents, patients with inconsistent meal patterns, and patients who have difficulty following administration instructions.[1]

What food-effect problem creates the largest excipient opportunity?

Isotretinoin has low aqueous solubility and depends on lipid digestion and intestinal solubilization for absorption. A conventional oil-filled softgel can perform adequately when taken with food, but exposure can decline when taken under low-fat or fasting conditions.

The key excipient objective is to increase and stabilize the apparent solubility of isotretinoin in gastrointestinal fluids. Candidate systems include:

• Self-emulsifying drug-delivery systems, or SEDDS
• Self-microemulsifying drug-delivery systems, or SMEDDS
• Mixed medium-chain and long-chain glycerides
• Solubilizers such as surfactants and co-surfactants
• Lipid-based formulations with precipitation inhibitors
• Amorphous solid dispersions
• Nanocrystal or nanosuspension systems
• Cyclodextrin or polymer-assisted solubilization, where toxicology and loading permit

The best commercial target is a formulation that reduces the food effect without increasing dose, variability, or adverse-event risk. A formulation that merely changes the oil vehicle but retains a substantial food dependency would have limited differentiation.

Which excipient technologies are most relevant?

Technology	Potential benefit	Primary development risk	Commercial value
SEDDS or SMEDDS	Better dispersion and reduced food dependence	Precipitation, capsule compatibility, surfactant tolerability	High
Medium-chain triglyceride system	Improved solubilization and manufacturability	Variable digestion and exposure	Moderate to high
Solid dispersion	Possible food-effect reduction and solid dosage flexibility	Physical stability and scale-up	High
Nanocrystal formulation	Higher dissolution rate	Particle aggregation and process complexity	Moderate
Cyclodextrin system	Aqueous solubilization	High excipient load and limited drug capacity	Low to moderate
Alternative oil blend	Lower cost or allergen reduction	Limited clinical differentiation	Low
Gelatin-free shell	Vegan or religious-use positioning	Mechanical and stability performance	Moderate

What formulations are protected by Claravis or competing isotretinoin products?

The original isotretinoin composition is no longer a strong exclusivity barrier. Isotretinoin has been marketed for decades, and conventional oral isotretinoin products have faced generic competition for many years. Claravis is therefore better analyzed as a commercial product and reference formulation than as a standalone patent moat.

The more relevant intellectual-property categories are:

1. Food-independent or reduced-food-effect formulations.
2. Lipid composition and self-emulsifying systems.
3. Particle-size, crystallinity, or solid-dispersion controls.
4. Stabilization systems that limit oxidation or isomerization.
5. Softgel shell composition and manufacturing processes.
6. Modified-release or alternative oral delivery systems.
7. Patient-use systems linked to dosing, packaging, or adherence.

A follow-on developer would need to distinguish between patent claims covering the active ingredient, a specific formulation, a manufacturing process, and a method of reducing the food effect. An excipient change alone does not create meaningful patent protection unless it produces a defined composition, performance profile, or manufacturing advantage.

The FDA Orange Book remains the primary source for listed patents and regulatory exclusivity associated with approved reference products.[2] For Claravis, the commercial barrier is primarily generic competition and risk management rather than an active, product-defining patent estate.

When does Claravis lose exclusivity, and what is the generic-entry risk?

Claravis has no meaningful remaining new-drug exclusivity barrier for ordinary generic entry. Isotretinoin products are approved through the abbreviated new drug application pathway, and multiple manufacturers have historically participated in the market.

Exclusivity issue	Claravis position
New chemical entity exclusivity	Expired
Pediatric exclusivity	Expired or not commercially material
Orphan exclusivity	Not applicable
Biosimilar exclusivity	Not applicable
Conventional generic entry	Established
Formulation-specific follow-on risk	Depends on separate patent and regulatory strategy
REMS burden	Applies to isotretinoin dispensing and prescribing controls

Generic manufacturers can challenge listed patents through Paragraph IV certifications when applicable. The commercial relevance of a Paragraph IV challenge depends on whether the listed patent covers the reference product, whether the patent remains enforceable, and whether the applicant seeks approval before patent expiry. For conventional Claravis-equivalent capsules, the more immediate risk is price erosion from existing generic suppliers rather than a future first-to-file patent challenge.

What is the FDA regulatory status of Claravis?

Claravis is an FDA-approved isotretinoin product subject to strict pregnancy-prevention controls. Isotretinoin is associated with severe fetal harm, and its distribution is controlled through the iPLEDGE REMS.[1,3]

The regulatory implications for excipient strategy are substantial:

• A new excipient may require toxicology justification and compatibility data.
• A new formulation may need comparative bioavailability studies.
• A reduced-food-effect claim would require controlled pharmacokinetic evidence.
• A change in exposure may affect safety, dose proportionality, and labeling.
• A 505(b)(2) application may be appropriate for a clinically differentiated formulation.
• An ANDA is more appropriate for a formulation that is pharmaceutically equivalent and bioequivalent to the reference product.
• A new dosage form or delivery mechanism may fall outside a straightforward generic strategy.

The iPLEDGE framework also limits the commercial benefit of a superior excipient system if the product does not simplify prescribing, dispensing, pregnancy testing, or patient adherence. Formulation differentiation alone will not eliminate the REMS burden unless FDA changes the applicable risk-management requirements.

How strong is the Claravis patent estate?

The conventional Claravis patent estate is commercially weak compared with newer specialty products. The active ingredient is long established, standard dosage strengths are familiar, and generic products are available.

Patent strength should be assessed separately across five dimensions:

Patent category	Likely strength for a new entrant
Isotretinoin composition of matter	Very low
Conventional softgel formulation	Low
Food-independent lipid formulation	Potentially moderate to high
Manufacturing and encapsulation process	Moderate if difficult to design around
Packaging or adherence system	Low to moderate unless tied to regulatory value

A follow-on formulation can create a stronger estate if it claims a specific excipient ratio, droplet-size distribution, dissolution profile, pharmacokinetic parameter, or stability result. Broad claims to “an isotretinoin formulation with improved absorption” are more vulnerable to written-description, enablement, obviousness, and anticipation challenges.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can target Claravis and competing isotretinoin products through platform technologies rather than commodity ingredients.

Food-independent isotretinoin delivery

This is the highest-value opportunity. A supplier with a validated lipid or solid-dispersion platform could offer:

• Reduced fasted-to-fed pharmacokinetic variability
• Lower dependence on high-fat meals
• Improved dose consistency
• Potentially lower total dose requirements
• A formulation suitable for 505(b)(2) development

The commercial proposition is strongest if the technology has prior regulatory use with lipophilic drugs and can be manufactured in a softgel or hard-shell capsule.

Soybean-oil replacement

Soybean oil is widely used in lipid formulations, but some developers may seek alternatives based on allergen management, supply-chain control, oxidation performance, or label simplification. Candidate replacements include medium-chain triglycerides, long-chain triglycerides, oleic-acid-rich oils, and synthetic glyceride systems.

A replacement oil is unlikely to support a premium product by itself. It becomes more valuable when combined with improved stability, reduced food effect, lower peroxide formation, or better capsule compatibility.

Gelatin-free capsule shells

Plant-based or non-gelatin shells could support patient and market preferences. However, the shell must maintain:

• Oxygen and moisture protection
• Mechanical integrity
• Fill compatibility
• Dissolution performance
• Stability over the proposed shelf life

A gelatin-free shell is more likely to support a niche product or licensing opportunity than a broad Claravis replacement unless combined with a meaningful pharmacokinetic advantage.

Oxidation and isomerization control

Isotretinoin is sensitive to light and oxidation. Excipient and packaging systems that reduce degradation can support longer shelf life, lower impurity levels, and improved manufacturing yield. Relevant measures include antioxidants, oxygen-control packaging, low-peroxide excipients, nitrogen processing, and light-protective blister systems.

Any antioxidant strategy must be evaluated for drug compatibility, impurity formation, and regulatory acceptability. Packaging improvements may provide a lower-risk development path than a major change to the drug-release formulation.

How does Claravis compare with Absorica and other isotretinoin products?

Absorica is the principal commercial comparator for formulation differentiation because it was developed around a lipid-based delivery system intended to reduce dependence on food. Its labeling permits administration without regard to meals, unlike conventional isotretinoin products that require administration with food.[4]

Product type	Food administration	Differentiation	Competitive implication
Claravis and conventional generics	With meals	Low-cost established formulation	High price pressure
Absorica	Without regard to meals under labeling	Lipid-based absorption strategy	Premium formulation benchmark
Absorica LD	Lower-dose lipid formulation platform	Dose and administration differentiation	Stronger specialty positioning
Future SEDDS or solid-dispersion product	Targeted reduction in food effect	Potential new 505(b)(2) product	Requires clinical differentiation

Absorica demonstrates that formulation differentiation can support a branded isotretinoin franchise despite generic competition. The commercial challenge is proving that the benefit matters to prescribers and patients enough to justify a price premium.

What licensing deals and partnership structures are most viable?

The most practical licensing targets are excipient platforms with human pharmacokinetic data and prior FDA exposure. A transaction may involve:

• An exclusive formulation license to a specialty pharmaceutical company
• A co-development agreement with an isotretinoin manufacturer
• A technology supply agreement for a proprietary lipid preconcentrate
• A contract development and manufacturing arrangement
• A 505(b)(2) asset sale after proof of concept
• A formulation-plus-packaging package aimed at generic manufacturers

Licensors should avoid relying on ingredient exclusivity. The defensible asset is the combination of formulation composition, manufacturing process, clinical performance, and regulatory file.

What generic launch scenarios exist for improved isotretinoin products?

Low-risk generic substitution

A manufacturer reproduces the conventional capsule profile and competes on cost, supply reliability, and contracting. This approach has limited margin but the lowest clinical and regulatory risk.

Differentiated generic-style product

A manufacturer improves shell composition, stability, packaging, or excipient sourcing without making a strong clinical claim. This can reduce manufacturing cost or supply risk but will not reliably support premium pricing.

505(b)(2) reduced-food-effect product

A developer uses a new formulation and seeks labeling that permits administration with less dependence on food. This has the highest commercial upside but requires pharmacokinetic development, safety review, manufacturing scale-up, and a defensible patent position.

Specialty formulation with adherence positioning

A product combines a simplified administration instruction, calendar packaging, electronic adherence support, and patient-focused dispensing. The REMS remains in place, but better usability may improve specialty-pharmacy adoption.

What manufacturing and IP barriers affect commercialization?

The key manufacturing barriers are capsule-fill homogeneity, drug crystallization, precipitation after dilution, oxidation, shell interaction, and scale-up of high-shear or solvent-based processes. A formulation that performs well in laboratory dissolution testing can fail during commercial manufacture if the lipid system changes viscosity, causes leakage, or produces variable fill weight.

The main IP barriers are formulation obviousness, freedom to operate around Absorica-related technology, process patents, and the difficulty of proving that a narrow excipient combination produces an unexpected clinical benefit. A developer should build the patent strategy around measurable performance, not a generic list of excipients.

Key Takeaways

• Claravis is a conventional isotretinoin softgel with long-established generic competition.
• Its main formulation weakness is dependence on administration with food.
• Food-independent absorption is the highest-value excipient opportunity.
• SEDDS, SMEDDS, lipid preconcentrates, and solid dispersions are the most commercially relevant platforms.
• Soybean-oil replacement and gelatin-free shells offer secondary differentiation but limited standalone pricing power.
• Isotretinoin has no biosimilar issue because it is a small-molecule drug.
• Conventional Claravis patent protection is commercially weak; new formulation claims would carry most of the defensible value.
• A clinically differentiated product would likely require a 505(b)(2) strategy rather than ordinary ANDA substitution.
• iPLEDGE remains a central regulatory and commercial constraint.
• The strongest licensing asset is a validated formulation platform with human pharmacokinetic data, scalable manufacturing, and patent claims tied to measurable performance.

FAQs

Can a new excipient make Claravis bioequivalent without a clinical trial?

Possibly, but the answer depends on the extent of formulation change and the regulatory pathway. A pharmaceutically equivalent product may use different inactive ingredients if it meets FDA requirements and demonstrates bioequivalence. A product claiming reduced food dependence or a new clinical advantage would require a more extensive development program.

Is soybean oil essential to isotretinoin absorption?

No. Soybean oil is one formulation vehicle, not a pharmacologic requirement. Other lipid systems may support absorption, but the substitute must maintain solubility, stability, capsule compatibility, and acceptable pharmacokinetics.

Can an isotretinoin formulation avoid the iPLEDGE REMS?

A formulation change does not automatically remove the REMS. The risk arises from isotretinoin exposure and fetal toxicity, so a new product would generally remain subject to applicable FDA pregnancy-prevention controls.

Is a liquid isotretinoin formulation commercially attractive?

It could support pediatric administration or patients who cannot swallow capsules, but the product would face taste masking, dose-measurement, light stability, oxidation, packaging, and dispensing challenges. A liquid format would likely require differentiated regulatory development.

What is the best patent strategy for a new Claravis alternative?

The strongest strategy would combine composition claims covering a defined excipient system with process claims, stability claims, and pharmacokinetic or dissolution limitations tied to reduced food dependence. Broad claims to isotretinoin and generic lipid vehicles would be less defensible.

References

1. U.S. Food and Drug Administration. (n.d.). Claravis (isotretinoin) capsules prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (n.d.). iPLEDGE Risk Evaluation and Mitigation Strategy.
4. U.S. Food and Drug Administration. (n.d.). Absorica and Absorica LD prescribing information.